Clinical Trial

Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018\_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate if Rentosertib (INS018\_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018\_055). In this study, Rentosertib (INS018\_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018\_055) works to treat Idiopathic Pulmonary Fibrosis.
Trial Details
NCT Number NCT07687459
Lead Sponsor InSilico Medicine Hong Kong Limited
Conditions Idiopathic Pulmonary Fibrosis
Enrollment 320 participants
Start Date 2026-08-30
Primary Completion 2029-10-30 (estimated)
Study Completion 2029-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07